Accsys Technologies (LSE:AXS), the Anglo-Dutch producer of the high-performance modified wood Accoya, delivered its most convincing results in years for the twelve months to 31 March 2026: record volumes, double-digit Revenue growth, adjusted EBITDA up 96% and a swing towards statutory profitability. For a company that spent years battling cost inflation, a troubled US start-up and a stretched balance sheet, the numbers read like the long-promised turnaround.
The headline asks whether that turnaround has finally arrived. The evidence is encouraging: margins are expanding, the US venture has stopped bleeding cash, and Leverage is falling. But Accsys still carries meaningful net debt, is exposed to a cyclical construction end-market, and must prove it can hit ambitious capacity and Margin targets.
What the Company Does
Accsys makes and licenses technology that chemically modifies fast-growing, sustainably sourced softwood into products with the durability and stability of tropical hardwood. Its flagship, Accoya, is used in windows, doors, cladding and decking, prized for a long guaranteed lifespan and low maintenance. Its core plant is at Arnhem in the Netherlands, complemented by an Accoya USA Facility in Kingsport, Tennessee, a 60%-owned joint venture that opened in 2024.
The Business also has a Tricoya stream, using the same acetylation chemistry to modify wood chips for panel products. Revenue comes from selling Accoya to distributors and manufacturers worldwide, plus licensing and its share of the US venture. End-markets are construction and renovation, giving Accsys structural exposure to sustainability trends, but also to the cyclicality of housing activity. Its moat is proprietary acetylation know-how and an established Accoya brand.
Why the Stock Is in Focus
The catalyst is the scale of the profit inflection. In a pre-close update in April 2026 and full preliminary results on 16 June 2026, Accsys revealed record global Accoya volumes of 77,237 cubic metres, up 21% year on year, with North American volumes up around 60%. Adjusted EBITDA nearly doubled, and the group swung from a heavy prior-year loss towards statutory break-even.
Just as important, the Accoya USA joint venture, long a drag on cash and sentiment, turned EBITDA-positive, a swing of more than €10m year on year. After a period defined by dilutive fundraising, restructuring and doubts about the US ramp-up, the market is focused on whether Accsys has reached a genuine, self-sustaining inflection point. Chief executive Dr Jelena Arsic van Os pointed to record volumes 'driving strong revenue growth, continued Market Share gains and significantly improved profitability.'
Latest Financial Picture
For the year to 31 March 2026, Accsys reported group revenue of €153m, up 12% (about 20% like-for-like), while aggregated revenue including its share of the US joint venture rose 24% to €183m. Adjusted EBITDA jumped 96% to €21.2m from €10.8m, lifting the margin to 11.6% from 7.3%, closing in on the 12% Phase I target. The statutory loss before tax narrowed sharply to €0.6m from €20.8m, and the group reported a profit after tax of €6.5m against a €22.9m loss the prior year.
Underlying Earnings Per Share turned positive at 2.1 cents (from a 5.0-cent loss), with statutory EPS of 2.7 cents and gross margin edging up to 30.9%. Net Debt eased to €41.4m from €42.6m, free Cash Flow rose to €10.2m, and leverage improved to 1.96x from 2.52x. The Accoya USA venture generated €50.5m of revenue (up 178%) and swung to a small €0.2m EBITDA profit. Management said trading was in line with FY27 expectations and on track against its Phase I FOCUS targets, guiding towards a roughly 100,000 cubic-metre run-rate. StockAnalysis.com showed the AIM-listed shares near 77p in mid-June 2026, valuing the group at about £187m.
The Bull Case
The operational turnaround is tangible. Record volumes, a 96% jump in adjusted EBITDA, expanding margins and a swing to statutory profit suggest Accsys has moved past its most acute problems. Critically, the Accoya USA joint venture reached EBITDA break-even, removing the biggest drag on group cash and de-risking the growth story in a large, under-penetrated market where volumes leapt around 60%.
Leverage is falling, free cash flow is rising, and the exit run-rate points towards the 100,000 cubic-metre ambition and a 12% EBITDA margin target. Structurally, Accsys rides a powerful Demand theme in durable, sustainable, lower-carbon building materials, supported by proprietary technology and a recognised brand. If the US plant keeps scaling and European demand holds, Operating Leverage could drive disproportionate profit growth.
The Bear Case
For all the progress, Accsys still carries net debt of €41.4m against modest cash of €17.4m, and the statutory result was only a whisker into profit. The recovery leans heavily on Volume growth in a construction and renovation end-market that is inherently cyclical and sensitive to rates, housing and consumer confidence.
The US joint venture has reached only break-even EBITDA, not robust profitability, and scaling it demands consistent execution after a difficult start. Accoya remains a premium, higher-priced product that can be squeezed in a downturn, and the group's history of dilutive fundraising and restructuring shows how quickly conditions can turn. Hitting the 100,000 cubic-metre and 12%-margin targets is plausible but not guaranteed, and any demand wobble would test a Balance Sheet that is improving but not yet comfortable.
What Could Move the Stock Next?
The key variables are volume and the US ramp-up. Investors will look for evidence that the Accoya USA venture can build on break-even EBITDA towards sustained profit, and that the group is progressing towards its roughly 100,000 cubic-metre run-rate and 12% margin target.
Near-term markers include trading updates through FY27, the AGM, and further debt reduction or refinancing of the convertible Loan notes. Construction and renovation demand, input costs and currency moves will shape margins, while licensing or capacity wins could add catalysts.
Outlook
On the evidence of the year to March 2026, Accsys has taken a decisive step. Record Accoya volumes, adjusted EBITDA nearly doubling, expanding margins, a swing to statutory profit and, most significantly, a US joint venture that has stopped consuming cash all point to a business that has moved from survival to progress.
Yet 'finally arrived' overstates it. The statutory profit is slim, net debt is still meaningful, and the growth engine depends on a cyclical construction market and on scaling the American plant to real profitability. On balance, Accsys looks like a credible turnaround in motion rather than a completed one: the direction of travel is convincingly positive, but the recovery's durability will be judged on whether the past year's volume, margin and cash-flow gains can be repeated and extended.






Please wait processing your request...